NovoCure (NVCR) Total Debt Growth (5y) (2020 - 2026)
NovoCure (NVCR) Total Debt Growth (5y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.45 Bn | 175.15 Bn | 6.27 Bn |
| 2 | Stryker | 128.93 Bn | 126.05 Bn | 3.81 Bn |
| 3 | Medtronic | 108.03 Bn | 98.81 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.19 Bn | 66.74 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.22 Bn | 44.55 Bn | 1.29 Bn |
| 6 | Dexcom | 28.24 Bn | 27.13 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.99 Bn | 25.70 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 27.01 Bn | 26.43 Bn | - |
| 9 | Koninklijke Philips | 23.72 Bn | 20.60 Bn | 2.07 Bn |
| 10 | NovoCure | 2.01 Bn | 1.57 Bn | 142.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.96% |
| Mar 31, 2026 | -18.97% |
| Dec 31, 2025 | -14.62% |
| Jun 30, 2025 | -8.17% |
| Mar 31, 2025 | -8.20% |
| Dec 31, 2024 | -8.22% |
| Sep 30, 2024 | -8.25% |
| Jun 30, 2024 | -8.28% |
| Mar 31, 2024 | 30.71% |
| Sep 30, 2023 | 30.65% |
| Jun 30, 2023 | 30.61% |
| Mar 31, 2023 | 30.58% |
| Dec 31, 2022 | 42.18% |
| Sep 30, 2022 | 42.22% |
| Jun 30, 2022 | 42.26% |
| Mar 31, 2022 | 42.30% |
| Dec 31, 2021 | 42.34% |
| Sep 30, 2021 | 42.37% |
| Jun 30, 2021 | 88.92% |
| Mar 31, 2021 | 89.02% |